MUC1 and cancer: Given this immune response, a C3-liposome-based vaccine formulation could possibly be used prophylactically as a vaccine to prevent the development of cancers with aberrant MUC1 expression, as well as in cancer treatment settings to enhance the immune recognition of MUC1-expressing cancer cells.